ATHENA (MO19391)
Laufzeit: 01.01.2007 - 31.12.2009
Kurzfassung
Open-label study of bevacizumab (Avastin) plus taxane monotherapy or in combination for the first-line treatment of patients with locally recurrent or metastatic breast cancer
Laufzeit: 01.01.2007 - 31.12.2009
Open-label study of bevacizumab (Avastin) plus taxane monotherapy or in combination for the first-line treatment of patients with locally recurrent or metastatic breast cancer
